Idactamab INT-001 represents the exciting clinical approach for managing selected oncological cancers. This antibody shows a unique process of function, specifically binding to CD38, a cell-surface protein present https://shaniaozvd411507.pointblog.net/idacta-mab-int-001-a-new-immunoglobulin-under-development-92204723